Royal Bank Of Canada Cti Biopharma Corp Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.2 - $6.01 $42,067 - $60,196	-10,016 Reduced 60.03%	6,669 $28,000
Q4 2022 Feb 14, 2023	BUY	$4.45 - $6.17 $55,495 - $76,946	12,471 Added 295.94%	16,685 $100,000
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $19,553 - $27,104	3,648 Added 644.52%	4,214 $24,000
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $1,856 - $3,279	523 Added 1216.28%	566 $3,000
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.86 $4 - $8	-3 Reduced 6.52%	43 $0

Q3 2021 Nov 15, 2021	BUY	$2.25 - $3.18 $6 - $9	3 Added 6.98%	46 $0
Q2 2021 Aug 16, 2021	BUY	$2.16 - $2.62 $92 - $112	43 New	43 $0

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.